Bertilimumab: Phase II started

Immune Pharmaceuticals began an open-label, Israeli Phase II trial to evaluate 2 doses of IV bertilimumab given 14 days apart in

Read the full 217 word article

How to gain access

Continue reading with a
two-week free trial.